NovAliX Partners with Kyowa Hakko Kirin
News Jan 17, 2013
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE
Plant Branching Chemical That Could Improve Crop ProductionNews
Researchers have used a range of analytical techniques to reveal a chemical that can reverse the limitation to the number of branches that plants make. These findings could lead to improved crop production.READ MORE
Crystal Structure Solved for an Enzyme That Plays a Key Role in DNA MethylationNews
Researchers have solved the crystal structure for an enzyme that plays a key role in DNA methylation, the process by which methyl groups are added to the DNA molecule.READ MORE